News
Anwita Biosciences Announced Today Dosing of First Patient in I...
anwitabio.com
of JS014” said Ziyang Zhong, Chief Executive Officer of Anwita . “JS014 is the first pro duct from our diverse portfolio of cytokines to enter the clinic . We are excited to follow the progress of JS014 in the Phase I trial . With a prolonged systemic exposure as a consequence of its extended half-life,
FOR IMMEDIATE - anwitabio.com
anwitabio.com
preclinical development or into IND-enabling status” said Ziyang Zhong, Chief Executive Officer of Anwita. “We are excited to share at SITC additional preclinical data demonstrating the potential of anti-PD1-IL-2 to drive targeted anti-tumor immune responses, and to present new data
sortiert nach Relevanz / Datum